PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.
Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Otros episodios de "OncoPharm"



No te pierdas ningún episodio de “OncoPharm”. Síguelo en la aplicación gratuita de GetPodcast.








